English

Simple item page
dc.contributor.authorSenol, S
dc.contributor.authorTasbakan, M
dc.contributor.authorPullukcu, H
dc.contributor.authorSipahi, OR
dc.contributor.authorSipahi, H
dc.contributor.authorYamazhan, T
dc.contributor.authorArda, B
dc.contributor.authorUlusoy, S
dc.date.accessioned2024-07-18T11:58:41Z
dc.date.available2024-07-18T11:58:41Z
dc.description.abstractTAYLOR & FRANCIS LTD
dc.identifier.issn1973-9478
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/7391
dc.language.isoArticle
dc.publisher1120-009X
dc.subjectThe aim of this observational prospective study was to compare the effect of fosfomycin tromethanol (FT) and carbapenems (meropenem or imipenem cilastatin) in the treatment of extended-spectrum beta-lactamase (ESBL)producing Escherichia coli-related complicated lower urinary tract infection (CLUTI). Inclusion criteria were: patients who were aged >18 yr with dysuria or problems with frequency or urgency in passing urine; those with >20 leukocytes/mm(3) in urine microscopy and culture-proven ESBL-producing carbapenem or FT-sensitive E. coli in the urine (>10(5) cfu/mm(3)); no leukocytosis or fever; and who were treated with FT (oral 3 g sachet x 1 every other night, three times) or carbapenems between March 2005 and January 2006 in our outpatient clinic and hospital. A total of 47 CLUTI attacks in 47 patients (27 FT group, 20 carbapenem group) were observed prospectively. Clinical and microbiological success in the carbapenem and FT groups was similar (19/20 vs 21/27 and 16/20 vs 16/27 p>0.05). Drug acquisition costs were significantly lower in the FT group (p<0.001). Although it is not a randomized controlled study, these data show that FT may be a suitable, effective and cheap alternative in the treatment of ESBL-producing E. coli-related CLUTI.
dc.titleEnglish
dc.typeRISK-FACTORS
dc.typeTROMETAMOL
dc.typeTHERAPY

Files

Collections

Web of Science Koleksiyonu